Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Alistair Nichol, Yaseen M. Arabi et al.|medRxiv|2021Cited by 137
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M. Arabi, Anthony Gordon, Lennie Derde et al.|Intensive Care Medicine|2021Cited by 100
Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trialLennie Derde, Ville Pettilä, Anthony Gordon et al.|Thorax|2025Cited by 12